South Africa

The financing forms part of Biovac’s expansion programme, which aims to increase the company’s annual manufacturing capacity to as many as 500 million vaccine doses.

Under the new arrangement, Remgro now owns 100% of Mediclinic’s Southern African operations through Mediclinic International, while IHL has taken full ownership of the Swiss-based Hirslanden Group.

The vaccine was registered earlier this month by the South African Health Products Regulatory Authority (SAHPRA), paving the way for large-scale importation and commercial distribution.

The Department of Health has begun distributing the injectable through an initial network of 360 health facilities located in high-burden districts.

The partnership introduces a new model of care that combines advanced remote monitoring, post-discharge support, and hospital-at-home services, allowing patients to remain connected to healthcare professionals throughout their recovery journey.

Edge Growth, in partnership with FNB’s Vumela Fund, backed Mia Healthcare at a pivotal stage of its development, reinforcing investor confidence in its business model and growth trajectory.

The funding comes as health authorities across the continent intensify efforts to contain the rapidly evolving outbreak linked to the Bundibugyo strain of the Ebola virus.

Globally, new HIV infections declined by 40% between 2010 and 2024, while the number of people requiring interventions for neglected tropical diseases dropped by 36% during the same period.

The pharmaceutical company submitted bids across several critical childhood immunisation categories, including the Pneumococcal Conjugate Vaccine (PCV10), Rotavirus vaccine, and paediatric Hepatitis B vaccine.